CureDuchenne, as an early investor in Avidity Biosciences, is excited to share the announcement of the Phase 1/2 EXPLORE44™ clinical trial of AOC 1044 in healthy volunteers and participants with Duchenne muscular dystrophy (DMD).
AOC 1044 is designed for people living with DMD amenable to exon 44 skipping (DMD44). EXPLORE44 is expected to enroll approximately 40 healthy volunteers and 24 participants with DMD44, ages seven to 27 years old. The EXPLORE44 trial will assess exon skipping and dystrophin protein levels in participants with DMD44.
CureDuchenne and Avidity Biosciences will be hosting a webinar in early December to present details of the trial to the Duchenne community, and answers questions. Registration will be open soon.
LINK TO Press Release: https://aviditybiosciences.investorroom.com/2022-10-11-Avidity-Biosciences-Announces-Phase-1-2-EXPLORE44-TM-Trial-of-AOC-1044-for-Duchenne-Muscular-Dystrophy-Mutations-Amenable-to-Exon-44-Skipping
SEE THE LETTER TO THE COMMUNITY